Efficacy and Safety of Continuous Risankizumab or Switching from Adalimumab to Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: Results from the Phase 3 IMMvent Trial

Kristian Reich, 1 Melissa Gooderham, 1 Diamant Thaci, 1 Jeffrey J. Crowley, 1 Caetirona Ryan, 1 James G. Krueger, 1 Tsen-Fang Tsai, 1 Mary Flack, 1 Yihua Gu, 1 Tianshuang Wu, 1 David A. Williams, 2 Elizabeth H. Z. Thompson, 1 – Carle Paul 1

1Scleroderma Research Institute, Hamburg, and Dermatologikum Berlin, Germany; 2School of Medicine, Queen’s University, Kingston, ON and SKN Centre for Dermatology and Probiotic Medical Research, Peterborough, ON, Canada; 3Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck Germany; 4Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA, United States; 5Charles’ Institute of Dermatology, University College Dublin, Ireland; 6Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, United States; 7Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; 8Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States; 9AbbVie Inc., North Chicago, IL, United States; 10AbbVie Inc., Redwood City, CA, United States; 11Paul Sabatier University and Larrey Hospital, Toulouse, France

STATISTICAL ANALYSES

– All primary and secondary endpoints were conducted on the intent-to-treat populations (all patients randomized at Week 0 for Part A and all-in-all randomized at Week 16 for Part B).
– A logistic regression model was fit for difference estimates stratified by baseline weight and prior TNF inhibitor exposure for categorical variables
– Analysis of covariance with treatment group, baseline value, and stratification factors in the model for continuous variables
– Numerical testing procedure for exclusions used to control for multiplicity
– Missing efficacy data were imputed as non-responders for categorical variables and test done from complete data set for continuous variables

SAFETY

– Safety analyses were conducted in all patients who received at least one dose of study drug

Figure 1. Study Design

Figure 2. Baseline Psoriasis Area and Severity Index (PASI)

Figure 3. Component (A) and Secondary (B) Endpoints at Week 16 (NIR)

Figure 4. Component (A) and Secondary (B) Endpoints at Week 44 among Patients Re-randomized

Figure 5. Percentage of Patients with Absolute PASI 90 and 11 at Week 16 (A) and Week 44 (B-C)